Sponsor content

Destroying cancer cells and providing antitumor immunity

NBE-Therapeutics is developing a novel class of immune-stimulatory antibody drug conjugates (iADCs) that not only target and destroy cancer cells, but also trigger long-lasting antitumor immunity.

Go to the profile of NBE Therapeutics
Sep 11, 2018
0
0
Like 0 Comment
Page of
Go to the profile of NBE Therapeutics

NBE Therapeutics

NBE-Therapeutics is a privately owned Swiss, Basel-based Biotech company that was founded in 2012 with the vision to develop next-generation ADCs improving treatment options for cancer patients. The company is financially backed by the Boehringer Ingelheim Venture Fund and additional private investors.

No comments yet.